02135 RAILY AESMED
- 0.148
- -0.004-2.63%
RAILY AESMED News
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
Ruili Medical Aesthetic (02135.HK) received an additional OTC share of 33.9938 million shares worth HK$5.031 million from Youxin Management Co., Ltd.
On April 30, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 30, Youxin Management Co., Limited increased its OTC share holdings of $Ruili Medical Beauty (02135.HK) by an average price of HK$0.148 per share on April 25, to a value of about HK$5.031 million. After the increase in holdings, Youxin Management Co., Limited's latest shareholding was 46.133 million shares, and the good position ratio increased from 2.91% to 8.28%. Picture source:
Ruili Medical Aesthetic (02135.HK) was granted an OTC share increase by Fu Haishu by 73.9522 million shares worth approximately HK$10.944,900
On April 30, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 30, Fu Haishu increased his OTC share holdings of $Ruili Medical Beauty (02135.HK) by $73.9522 million on April 25 at an average price of HK$0.148 per share, worth about HK$10.944,900. After increasing his holdings, Fu Haishu's latest shareholding was 296 million shares, with a good position ratio of 53.10%. Additional information: Shares were offered on the basis of obtaining 1 share for every 3 issued shares, and a total of 73,952,231 shares were obtained, of which 1 share was an additional allocation adjusted by the securities bank.
Ruili Medical & Aesthetic (02135.HK) issued and allotted approximately 139 million new shares under the share offering
On April 25, Ge Longhui (02135.HK) issued an announcement. On April 25, 2024, approximately 139 million new shares will be issued and allocated in accordance with the share offering.
Ruili Medical Aesthetic (02135): The share offering was oversubscribed by about 31.7% and raised about HK$19.2 million
According to Zhitong Finance App News, Ruili Medical & Aesthetic (02135) announced that since all conditions contained in the underwriting agreement have been met, and the underwriter did not terminate the underwriting agreement before the final termination time limit, the stock offering was becoming unconditional at 4:00 p.m. on April 18, 2024 (Thursday). The net proceeds from the stock offering were approximately HK$19.2 million. In total, it has received 8 provisional quota notices and valid applications under additional application forms, involving a total of approximately 183 million shares offered, which is equivalent to about 131.7% of the total number of shares offered for subscription under the offering. Based on the above results, shares were sold
瑞麗醫美(新)：2023年報
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
Ruili Medical & Aesthetic (02135) announced annual results, loss attributable to shareholders of 32.457 million yuan, an increase of 103.99% year-on-year
According to the Zhitong Finance App, Ruili Medical & Aesthetic (02135) announced annual results for the year ended December 31, 2023. The group achieved revenue of 189 million yuan (RMB, same below) during the period, an increase of 15.11% over the previous year; losses attributable to shareholders were 32.457 million yuan, an increase of 103.99% over the previous year; and the basic loss per share was 7.77 points. According to the announcement, the main reason for the increase in revenue and continued losses is that in the first month of 2023, the business of medical institutions in Zhejiang and Anhui regions was still affected by the large-scale COVID-19 outbreak, which prevented most customers from visiting the group's institutions, making the company
瑞麗醫美：截至2023年12月31日止年度年度業績公告
Ruili Medical & Aesthetic (02135) cut 1,671 billion shares due to share consolidation on a “5 and 1” basis
Ruili Medical & Aesthetic (02135) issued an announcement to cut 1,671 billion shares due to share consolidation on a “5 and 1” basis...
Ruili Medical & Aesthetic (02135): The share merger will take effect on March 19
Ruili Medical & Aesthetic (02135) issued an announcement. Since all conditions for the share merger have been met, the share merger will be 202...
Raily Aesthetic Medicine Forecasts Wider Loss in 2023
Raily Aesthetic Medicine International Holdings (HKG:2135) forecasts its loss to widen to 32 million yuan in 2023 from 16 million yuan in 2022, according to a Thursday filing with the Hong Kong bourse
Ruili Medical Aesthetic (02135) Fa Ying Guang expects losses due to parent company owners of about 32 million yuan to double year-on-year in 2023
Ruili Medical & Aesthetic (02135) announced that the group expects revenue of about RMB 189 million in 2023, an increase over the previous year...
Ruili Medical & Aesthetic (02135.HK) proposes a “3 to 1” share offering for the “5 in 1” consolidated shares
On February 26, Gelonghui (02135.HK) issued an announcement. The board of directors proposed a share consolidation based on the basis of merging every 5 existing shares in the company's share capital into 1 consolidated share. The share consolidation is subject to approval by shareholders by voting at the special shareholders' meeting before it can actually take place. The Company proposes to issue up to 141 million shares of the offering at a subscription price of HK$0.148 per share of the 3 consolidated shares held by eligible shareholders, with a maximum total proceeds of approximately HK$20.8 million (before deducting expenses) through a share offering. Net proceeds from the sale of shares
Ruili Medical & Aesthetic (02135.HK) grants 47.43 million share options
Gelonghui, Feb. 23 | Ruili Medical & Aesthetic (02135.HK) announced that after the 47.43 million share options previously granted by the company expired, the board of directors has decided to grant 47.43 million share options to certain eligible persons (i.e. six employees of the Group) in accordance with the share option plan adopted by the shareholders on December 4, 2020. The exercise price of the shares was HK$0.122 per share.
Express News | Fangzheng Securities: The cosmetics, medical and aesthetic industries are expected to usher in strong breakthroughs
The Little Peak of Medicine and Aesthetics is here! There was a wave of beauty concentrated before the Spring Festival, but why did the practitioners continue to complain? |Industry Watch
Ultrasound cannons are booked three days in advance, and the administration is transferred to the front desk to receive customers... A Financial Association reporter recently visited several medical and aesthetic institutions in Chengdu and found that as the Spring Festival approaches, there has been a marked increase in the number of consumers visiting hospitals for consultation and treatment, and some popular programs require advance reservations.
Ruili Medical & Aesthetic (02135.HK) grants 48.63 million share options
Gelonghui, January 26, 丨 Ruili Medical Beauty (02135.HK) issued an announcement. The board of directors has decided to grant 48.63 million share options to a number of eligible persons (that is, the three employees of the Group) in accordance with the share option plan adopted by the shareholders on December 4, 2020. The exercise price of the share options is HK$0.115 per share.
Medical and aesthetic recovery stalled in the second half of the year, triggering a price war. Listed companies target a new “optoelectronic anti-aging” track|year-end inventory
Financial Services Association, December 26 (Reporter He Fan) As the end of the year progresses, the medical and aesthetic market does not seem to be “in full swing” as predicted at the beginning of the year.
RAILY AESMED: Interim Report 2023
Analysis
Price Target
No Data
